Welcome to our dedicated page for Insmed news (Ticker: INSM), a resource for investors and traders seeking the latest updates and insights on Insmed stock.
Insmed Inc (NASDAQ: INSM) is a global biopharmaceutical leader developing innovative therapies for rare pulmonary diseases and chronic inflammatory conditions. This news hub provides investors and healthcare professionals with essential updates on clinical trials, regulatory milestones, and therapeutic advancements.
Access real-time information about Insmed's FDA submissions, partnership announcements, and research breakthroughs. Our curated collection includes updates on ARIKAYCE commercialization, brensocatib clinical studies, and novel inhalation technologies like TPIP platform developments.
Key content categories include treatment approvals, scientific conference presentations, patent filings, and manufacturing expansions. All materials are sourced directly from company filings and verified industry publications to ensure accuracy.
Bookmark this page for streamlined access to Insmed's latest developments in targeted pulmonary therapy and rare disease research. Check regularly for critical updates affecting treatment accessibility and clinical progress.
Insmed presented positive data from its Phase 3 ARISE study of ARIKAYCE® (amikacin liposome inhalation suspension) at the American Thoracic Society 2024 International Conference. The study evaluated patients with nontuberculous mycobacterial (NTM) lung disease caused by Mycobacterium avium complex (MAC). ARIKAYCE combined with a macrolide-based regimen showed significantly greater improvements in respiratory symptoms and higher rates of culture conversion compared to the macrolide regimen alone. Quality of Life-Bronchiectasis (QOL-B) scores improved through Month 7 for ARIKAYCE patients, whereas improvements plateaued or worsened for the comparator group after Month 3. No patients developed resistance to ARIKAYCE or macrolides. Adverse event rates were higher in the ARIKAYCE arm but were consistent with expected safety profiles.
Insmed Incorporated reported total revenue of $75.5 million for the first quarter of 2024, showing 16% growth over the same period in 2023. The company highlighted positive safety and tolerability data from TPIP studies and encouraging results from PAH trials. They reiterated their 2024 revenue guidance of $340-360 million for global ARIKAYCE. Insmed continues to focus on commercial expansion, R&D for brensocatib and TPIP, and early-stage research programs.
Insmed Incorporated (Nasdaq:INSM) will present at the BofA Securities Health Care Conference 2024, aiming to transform the lives of patients with serious and rare diseases. The fireside chat will take place on May 14, 2024, at 2:20 p.m. PT (5:20 p.m. ET) in Las Vegas, NV. The webcast will be accessible on the company's investor relations website for 30 days post-event.
Insmed Incorporated (INSM) granted inducement awards to 63 new employees as a material inducement to their employment. The employees received options to purchase 410,300 shares of Insmed common stock at an exercise price of $25.59 per share. The options have a 10-year term and a four-year vesting schedule.
FAQ
What is the current stock price of Insmed (INSM)?
What is the market cap of Insmed (INSM)?
